Halal, with purification
Fidson Healthcare passes the business-activity screen and the financial screens under the AAOIFI Standard. Because a share of its income is non-permissible, the matching portion of any dividend you receive should be given away.
NGX: FIDSON · Healthcare · Screened 4 Sept 2026 · H1 2026 accounts
Fidson Healthcare Plc manufactures and distributes pharmaceutical products in Nigeria. The company was incorporated in 1995 and is headquartered in Lagos, with a WHO-compliant manufacturing plant in Ogun State that produces over 120 million bottles of Large Volume Parenterals annually and remains Nigeria's only manufacturer of glass-ampoule injectables. It operates 11 built-for-purpose depots across Nigeria and is actively exploring new African markets, with a workforce of 732 employees as at 31 December 2025.
The company reports three segments: Ethical Products, covering drugs, injectables and infusions sold only on a valid prescription; Over-the-Counter, covering products sold directly to consumers without a prescription; and Consumer Healthcare Products. Its portfolio spans anti-infective and anti-malarial products, central nervous system medicines, cough and cold remedies, gastrointestinal medicines, supplements, topical and dermatological preparations, vitamins and minerals, and ophthalmic solutions.
For 2025, the company recorded revenue of N119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the N100 billion annual revenue mark. Ethical drugs accounted for N77.8 billion (70.7%), with OTC products contributing N36.37 billion (29.3%). Profit before tax rose 94% to N14.96 billion, and profit after tax surged 125% to N9.88 billion. The company proposed a dividend of N3.6 billion, translating to N1.50 per share. The company has partnered with the International Finance Corporation to expand Nigeria's pharmaceutical production capacity, and is actively working toward becoming the largest pharmaceutical manufacturer in Sub-Saharan Africa.
Three segments: Ethical Products, Over-the-Counter and Consumer Healthcare. Prescription medicines represent 70.7% of net sales and OTC products 29.3%.
Yes, with purification. As of 4 September 2026, Fidson Healthcare (FIDSON) is halal to own under the AAOIFI Standard, provided you purify the non-permissible portion of any dividend you receive.
The dividend is permissible to receive once purified. Qistal publishes the purification rate for the current accounts period inside your compliance report, so you can work out the exact amount to give away.
Qistal re-screens every NGX ticker when new audited or interim accounts are filed. This page always shows the date of the most recent screen.
Yes. Compliance drifts as a company borrows, raises cash, or changes its business mix, so a verdict describes a moment rather than a permanent status.